The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mironova Yu.S.

Siberian State Medical University, Tomsk, Russia

Zhukova I.A.Жукова Ирина Александровна

Siberian State Medical University, Tomsk

Zhukova N.G.

Siberian State Medical University, Tomsk, Russia

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Izhboldina O.P.

Siberian State Medical University, Tomsk

Latypova A.V.

Siberian State Medical University, Tomsk, Russia

Parkinson’s disease and glutamate excitotoxicity

Authors:

Mironova Yu.S., Zhukova I.A.Жукова Ирина Александровна, Zhukova N.G., Alifirova V.M., Izhboldina O.P., Latypova A.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6‑2): 50‑54

DOI: 10.17116/jnevro201811806250

Read: 2752 times

Contact the author
Table of contents

PARKINSON’S DISEASE AND GLUTAMATE EXCITOTOXICITY
PARKINSON’S DISEASE AND GLUTAMATE EXCITOTOXICITY

To cite this article:

Mironova YuS, Zhukova IAЖукова Ирина Александровна, Zhukova NG, Alifirova VM, Izhboldina OP, Latypova AV. Parkinson’s disease and glutamate excitotoxicity. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6‑2):50‑54. (In Russ.)
https://doi.org/10.17116/jnevro201811806250

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Musculoskeletal diso­rders in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):6-10
Sele­ction of patients with Parkinson’s disease for inte­rventional therapies: A review of available tools — scales and questionnaires. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):11-17
«Brain—gut—microbiome» axis in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):18-23
Perceptions of the disease and self-assessment of the quality of life in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):24-31
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14
Dyna­mics of permeability of the blood-brain barrier after FUS thalamotomy acco­rding to contrast-enhanced MRI. Burdenko's Journal of Neurosurgery. 2025;(4):51-60
Change of speech diso­rders during bila­teral deep stimulation of the subthalamic nucleus of the brain in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):59-65
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Current aspe­cts of the rela­tionship between depression and cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):66-74
Abstract:

Objective. To measure the concentration of glutamate in the serum of patients with Parkinson's disease (PD) and determine its association with clinical variants of disease course. Material and methods. One hundred and ten patients with PD and 90 healthy people were examined. Glutamate concentration in the blood serum was determined with a spectrophotometric method. Results and conclusion. Patients with Parkinson's disease had significantly higher levels of serum glutamate compared with healthy subjects (p<0,0001). Patients with a tremor-dominant subtype had significantly higher levels of serum glutamate compared to those in patients with akinetic-rigid and mixed subtypes. The results obtained allow us to expand our understanding of the pathogenesis of this disease. Changes in the concentration of glutamate may reflect neurodegenerative process in PD.

Keywords:

Parkinson's disease
non-motor symptoms
glutamate
excitotoxicity

Authors:

Mironova Yu.S.

Siberian State Medical University, Tomsk, Russia

Zhukova I.A.Жукова Ирина Александровна

Siberian State Medical University, Tomsk

Zhukova N.G.

Siberian State Medical University, Tomsk, Russia

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Izhboldina O.P.

Siberian State Medical University, Tomsk

Latypova A.V.

Siberian State Medical University, Tomsk, Russia

Close metadata

References:

  1. Jankovic J. The Evolution of Diagnosis in Early Parkinson Disease. Archives of Neurology. 2000;57(3):369. https://doi.org/10.1001/archneur.57.3.369
  2. Devos D, Lebouvier T, Lardeux B, Biraud M, Rouaud T, Pouclet H, Coron E, Bruley des Varannes S, Naveilhan P, Nguyen JM, Neunlist M, Derkinderen P. Colonic inflammation in Parkinson’s disease. Neurobiology of disease. 2013;50:42-48. https://doi.org/10.1016/j.nbd.2012.09.007
  3. Freitas ME, Fox SH. Nondopaminergic treatments for Parkinson’s disease: current and future prospects. Neurodegenerative disease management. 2016;6(3):249-268. https://doi.org/10.2217/nmt-2016-0005
  4. Himmelberg MM, West RJH, Elliott CJH, Wade AR. Abnormal visual gain control and excitotoxicity in early-onset Parkinson’s disease Drosophila models. Journal of Neurophysiology. 2018;119(3):957-970. https://doi.org/10.1152/jn.00681.2017
  5. Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends in Neurosciences. 2003;26(12):696-705. https://doi.org/10.1016/j.tins.2003.09.017
  6. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflügers Archiv — European Journal of Physiology. 2010;460(2):525-542. https://doi.org/10.1007/s00424-010-0809-1
  7. Carrillo-Mora P, Silva-Adaya D, Villaseñor-Aguayo K. Glutamate in Parkinson’s disease: Role of antiglutamatergic drugs. Basal Ganglia. 2013;3(3):147-157. https://doi.org/10.1016/j.baga.2013.09.001
  8. Rainesalo S, Keränen T, Palmio J, Peltola J, Oja SS, Saransaari P. Plasma and Cerebrospinal Fluid Amino Acids in Epileptic Patients. Neurochemical Research. 2004;29(1):319-324. https://doi.org/10.1023/b:nere.0000010461.34920.0c
  9. Miulli DE, Norwell DY, Schwartz FN. Plasma concentrations of glutamate and its metabolites in patients with Alzheimer’s disease. The Journal of the American Osteopathic Association. 1993;93(6):670-676.
  10. Ilżecka J, Stelmasiak Z, Solski J, Wawrzycki S, Szpetnar M. Plasma amino acids concentration in amyotrophic lateral sclerosis patients. Amino Acids. 2003;25(1):69-73. https://doi.org/10.1007/s00726-002-0352-2
  11. Ivanova SA, Loonen AJM, Pechlivanoglou P, Freidin MB, Al Hadithy AFY, Rudikov EV, Zhukova IA, Govorin NV, Sorokina VA, Fedorenko OY, Alifirova VM, Semke AV, Wilffert B. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Translational Psychiatry. 2012;2(1): e67-e67. https://doi.org/10.1038/tp.2011.66
  12. Jiménez-Jiménez FJ, Molina J, Vargas C, Gómez P, Navarro J, Benito-Leon J, Ortí-Pareja M, Gasalla T, Cisneros E, Arenas J. Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson’s disease. Journal of the neurological sciences. 1996;141(1-2):39-44. https://doi.org/10.1016/0022-510x(96)00115-3
  13. Mally J, Szalai G, Stone TW. Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson’s disease. Journal of the Neurological Sciences. 1997;151(2):159-162. https://doi.org/10.1016/s0022-510x(97)00119-6
  14. Kuiper MA, Teerlink T, Visser JJ, Bergmans PLM, Scheltens P, Wolters ECh. L-Glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson’s disease, multiple system atrophy, and Alzheimer’s disease patients. Journal of Neural Transmission. 2000;107(2):183-189. https://doi.org/10.1007/s007020050016
  15. Figura M, Kuśmierska K, Bucior E, Szlufik S, Koziorowski D, Jamrozik Z, Janik P. Serum amino acid profile in patients with Parkinson’s disease. PLOS ONE. 2018;13(1):0191670. https://doi.org/10.1371/journal.pone.0191670
  16. Shimmura C, Suda S, Tsuchiya KJ, Hashimoto K, Ohno K, Matsuzaki H, Iwata K, Matsumoto K, Wakuda T, Kameno Y, Suzuki K, Tsujii M, Nakamura K, Takei N, Mori, N. Alteration of Plasma Glutamate and Glutamine Levels in Children with High-Functioning Autism. PLoS ONE. 2011;6(10): 25340. https://doi.org/10.1371/journal.pone.0025340
  17. Lei S, Zavala-Flores L, Garcia-Garcia A, Nandakumar R, Huang Y, Madayiputhiya N, Stanton RC, Dodds ED, Powers R, Franco, R. Alterations in Energy/Redox Metabolism Induced by Mitochondrial and Environmental Toxins: A Specific Role for Glucose-6-Phosphate-Dehydrogenase and the Pentose Phosphate Pathway in Paraquat Toxicity. ACS Chemical Biology. 2014;9(9):2032-2048. https://doi.org/10.1021/cb400894a
  18. Gao HC, Zhu H, Song CY, Lin L, Xiang Y, Yan ZH, Bai GH, Ye FQ, Li XK. Metabolic Changes Detected by Ex Vivo High Resolution 1H NMR Spectroscopy in the Striatum of 6-OHDA-Induced Parkinson’s Rat. Molecular Neurobiology. 2012;47(1):123-130. https://doi.org/10.1007/s12035-012-8336-z
  19. Hawkins RA. The blood-brain barrier and glutamate. The American Journal of Clinical Nutrition. 2009;90(3):867-874. https://doi.org/10.3945/ajcn.2009.27462bb
  20. Kortekaas R, Leenders KL, van Oostrom JCH, Vaalburg W, Bart J, Willemsen ATM, Hendrikse NH. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Annals of Neurology. 2005;57(2):176-179. https://doi.org/10.1002/ana.20369
  21. Shtok VN, Fedorova NV. Bolezn’ Parkinsona. Ekstrapiramidnye rasstroistva. Rukovodstvo po diagnostike i lecheniyu. M.: Medpress-inform; 2002. (In Russ.)
  22. Levin OS, Fedorova NV. Bolezn’ Parkinsona. 3-e izdanie. M.: Medpress-inform; 2016. (In Russ.)
  23. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson’s disease. Movement Disorders. 2004;19(9):1020-1028. https://doi.org/10.1002/mds.20213
  24. Nasreddine ZS, Phillips NA, Bédirian, V., Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. Journal of the American Geriatrics Society. 2005;53(4):695-699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
  25. Buysse DJ, Hall ML, Strollo PJ, Kamarck TW, Owens J, Lee L, Reis SE, Matthews KA. Relationships between the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and clinical/polysomnographic measures in a community sample. Journal of clinical sleep medicine. 2008; 4(6):563.
  26. Pallant JF, Tennant A. An introduction to the Rasch measurement model: An example using the Hospital Anxiety and Depression Scale (HADS). British Journal of Clinical Psychology. 2007;46(1):1-18. https://doi.org/10.1348/014466506x96931
  27. Nikitina AV, Fedorova NV. Dopamine dysregulation syndrome in Parkinson’s disease. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2013;1:42-46. (In Russ.)
  28. Buhmann C, Rizos A, Emmans D, Jost WH. Interkulturelle Adaption der AIMS in deutscher Sprache. Der Nervenarzt. 2016;87(4):411-417. https://doi.org/10.1007/s00115-016-0099-8
  29. Alfredsson G, Wiesel FA, Tylec A. Relationships between glutamate and monoamine metabolites in cerebrospinal fluid and serum in healthy volunteers. Biological Psychiatry. 1988;23(7):689-697. https://doi.org/10.1016/0006-3223(88)90052-2
  30. Ghaemi M, Raethjen J, Hilker R, Rudolf J, Sobesky J, Deuschl G, Heiss WD. Monosymptomatic resting tremor and Parkinson’s disease: a multitracer positron emission tomographic study. Movement Disorders. 2002;17(4):782-788. https://doi.org/10.1002/mds.10125
  31. Benamer HTS, Oertel WH, Patterson J, Hadley DM, Pogarell O, Höffken H, Grosset DG. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. Baseline and 3-month observations. Movement Disorders. 2003;18(9):977-984. https://doi.org/10.1002/mds.10482
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.